NAD+ and Peptide Therapy: The Cellular Longevity Revolution
NAD+ and Peptide Therapy: The Cellular Longevity Revolution
Key Takeaways
- NAD+ levels decline by approximately 50% between ages 20 and 60, impacting cellular energy production and DNA repair
- Peptide-based NAD+ precursors show superior bioavailability compared to oral supplements in clinical studies
- Research suggests NAD+ therapy may support mitochondrial function,